Furthermore, chemotherapy induction and the possibility to optimise the association with EGFr antibody warrants further studies with the combination irinotecan–cisplatin and radiotherapy in patients with oesophageal cancer. The gene discussed is EGFR; the disease is carcinoma of esophagus.